News headlines about Sorrento Therapeutics (NASDAQ:SRNE) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.2991234740104 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

A number of brokerages have issued reports on SRNE. Oppenheimer set a $6.00 price objective on shares of Sorrento Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 15th. HC Wainwright set a $20.00 price objective on shares of Sorrento Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Six analysts have rated the stock with a buy rating, Sorrento Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.50.

Sorrento Therapeutics (NASDAQ:SRNE) traded up $0.05 during trading on Monday, hitting $2.30. 365,700 shares of the stock were exchanged, compared to its average volume of 830,696. Sorrento Therapeutics has a 1 year low of $1.50 and a 1 year high of $6.08. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.18.

TRADEMARK VIOLATION WARNING: “Sorrento Therapeutics (SRNE) Earning Somewhat Favorable News Coverage, Analysis Finds” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/04/sorrento-therapeutics-srne-earning-somewhat-favorable-news-coverage-analysis-finds.html.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.

Insider Buying and Selling by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.